A data-driven approach to clinical trial patient samples
Ana Todorovic, Sophie Gibbons, Philip Craig, Benjamin Fell IntroductionPsychotropic drug trials often involve a substantial period of patient recruitment. Psychiatrists…
Publications
Read More
Patient and Public Involvement Co-Development of a Route to Record-Level Data Access to Akrivia Health’s Secondary Healthcare Dataset
Names: Panagiota Kontari, Sophie Gibbons, Simon Pilinger, Elizabeth Ford, Benjamin Fell Background Using electronic health records (EHRs) as a source…
Identifying Predictors of Suicide in Severe Mental Illness: A Feasibility Study of a Clinical Prediction Rule (Oxford Mental Illness and Suicide Tool or OxMIS)
Background: Oxford Mental Illness and Suicide tool (OxMIS) is a brief, scalable, freely available, structured risk assessment tool to assess suicide risk in…
Is Regulation A Barrier to Innovation?
Is Regulation A Barrier to Innovation? Yes. Undeniably, unequivocally, yes. That is not a particularly satisfying answer, is it? The…
The status of current clinical practice in diagnosis of young onset dementia in England
Findings from the Angela Project Neuropsychiatry and behavioural neurology/assessment/measurement of neuropsychiatric/behavioural and psychological symptoms Background The presentation of dementia in…
Enhancing mental health research with better context for clinical concepts within EHRs
Our approach to accelerating research is grounded in the principle of data protection by design and default. The technologies and…
Why AI?
As we know, medical records can cover a long history of diseases (as Akrivia Health has found up to ninety…
What is Natural Language Processing (NLP)?
Natural Language Processing (NLP) is a form of Artificial Intelligence which processes language. Natural Language Processing (NLP) has existed for…
The acceleration of clinical trials through the optimisation of Akrivia Health’s platform
It is difficult to imagine the world of science without its laws dictating the need for clinical trials. Most probably…
The necessity of personalised data in precision medicine- A programme by Akrivia Health
It is probably true to say one of the most terrifying aspects of Alzheimer’s Disease (AD) is in its very…
The Burden associated with, and management of difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom
Background: Major depressive disorder (MDD) is common and often has sub-optimal response to treatment. Difficult-to-treat depression (DTD) is a new…
DCMS Data Reform Consultation Response
Introduction Akrivia Health works with a network of 16 mental healthcare organisations (the Akrivia Network) providing them with a service.…
MHRA Consultation Response
MHRA Consultation on Proposals for Legislative Changes to Clinical Trials Introduction Akrivia Health works with a network of 16 mental…
Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model
Abstract Background Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of…
Associated mortality risk of atypical antipsychotic medication in individuals with dementia
BACKGROUND Antipsychotic medications such as risperidone, olanzapine and aripiprazole are used to treat psychological and behavioural symptoms among dementia…
Validation of UK Biobank data for mental health outcomes: A pilot study using secondary care electronic health records
Highlights Linking UK Clinical Record Interactive Search (UK-CRIS) and UK Biobank. Comparison of diagnosis for 854 individuals present in both…